NR 503 MIDTERM EXAM REVIEW FINAL EXAM
NR 503 MIDTERM EXAM REVIEW
FINAL EXAM. GRADED A+.
WITH QUESTIONS AND 100%
VERIFIED ANSWERS. LATEST
UPDATE
1. The nurse practitioner is reviewing a recent study that utilizes analytic
epidemiology by means of a cohort study design. The cohort study design
informs the practitioner about which of the following:
Outcomes that develop from an exposure
2. A group of providers have implemented population-based intervention
and are now assessing the efficacy of the intervention. Which of the
following would be an example of a population based outcome?
Decreased mortality rate compared to previous year
3. Appraisal of research publications is critical as providers assess for
relevance to population health. Which of the following items should be
considered during the appraisal process? Select all that apply.
Outcome measure, Transparency, Internal Validity
4. What is being compared in a cohort study design?
The incidence of a disease between exposed and non-exposed individuals
5. Analytic epidemiology is best described as:
Studies that investigate origins factors of health-related events
6. You are part of a research group investigating association between
,NR 503 MIDTERM EXAM REVIEW FINAL EXAM
exposure and disease. Which study design is a best fit for this type of
study:
Case-Control Study
7. The provider is concerned about what appears to be an increase in the
mortality rate for their community. Mortality is an example of which of
the following:
Vital statistic
8. An example of a tertiary prevention measure for chronic obstructive
pulmonary disease is: Pulmonary Rehabilitation
9. Which of the following statements best describe efficacy?
It is an estimate of the benefit of treatment under
ideal conditions It is an estimate of the reduction
of disease in treated groups
10. A study is conducted for a pharmaceutical agent that has shown promise
for reducing heart disease among women. In order to more fully test the
agent, an additional study is done restricting the participants to be
randomized to those who have a history of hypertension. Which of the
following advantages cannot be claimed by the researchers?
, NR 503 MIDTERM EXAM REVIEW FINAL EXAM
The generalizability of the study is increased
11. What is the main advantage of the randomization of the 168 study
participants to one of the two drug treatment groups?
Reduces selection bias
12. After entry into the study, patients were first classified into three groups,
those who had a previous AMI, those with a first AMI who were at high risk
for other cardiovascular diseases such as congestive heart failure, and
those with a first AMI who were at low risk for other cardiovascular
diseases. Which term best describes the study design?
Randomized clinical trial with stratified randomization
13. After assignment to treatment group, 77% of those in the placebo group
were men, while 80% of those in the drug X group were men. Which
statement is most likely to be true?
Randomization was successful since the investigators did not alter the
selection of participants in either group in order to ensure equal
percentages of men
14. A preliminary analysis was conducted after 6 months and found that 87%
of participants in the placebo group and 85% of those in the drug X group
had taken more than 90% of their prescribed dosages. Which statement
best describes this finding?
The characteristics of patients who failed to comply with the treatment dosages should be
assessed as they may differ from those who complied
15. Which of the following statements best describes the reason for conducting
the study as a double- blind trial?
Double blinding ensures that potential biases regarding selection, follow-up,
and analysis can be reduced
A multicenter double-blind randomized study was carried out to compare
the effect of drug X with that of a placebo in patients surviving acute
myocardial infarction (AMI). Treatment with the drug started 7 days after
infarction in 1,884 patients, 52% of all persons who were evaluated for
entry into the study. 945 participants were randomized to treatment with
drug X while 939 were assigned to the placebo group. Patients were then
followed for 12 months for reinfarction. There were 152 deaths in the
placebo group and 98 in the group receiving drug X.
NR 503 MIDTERM EXAM REVIEW
FINAL EXAM. GRADED A+.
WITH QUESTIONS AND 100%
VERIFIED ANSWERS. LATEST
UPDATE
1. The nurse practitioner is reviewing a recent study that utilizes analytic
epidemiology by means of a cohort study design. The cohort study design
informs the practitioner about which of the following:
Outcomes that develop from an exposure
2. A group of providers have implemented population-based intervention
and are now assessing the efficacy of the intervention. Which of the
following would be an example of a population based outcome?
Decreased mortality rate compared to previous year
3. Appraisal of research publications is critical as providers assess for
relevance to population health. Which of the following items should be
considered during the appraisal process? Select all that apply.
Outcome measure, Transparency, Internal Validity
4. What is being compared in a cohort study design?
The incidence of a disease between exposed and non-exposed individuals
5. Analytic epidemiology is best described as:
Studies that investigate origins factors of health-related events
6. You are part of a research group investigating association between
,NR 503 MIDTERM EXAM REVIEW FINAL EXAM
exposure and disease. Which study design is a best fit for this type of
study:
Case-Control Study
7. The provider is concerned about what appears to be an increase in the
mortality rate for their community. Mortality is an example of which of
the following:
Vital statistic
8. An example of a tertiary prevention measure for chronic obstructive
pulmonary disease is: Pulmonary Rehabilitation
9. Which of the following statements best describe efficacy?
It is an estimate of the benefit of treatment under
ideal conditions It is an estimate of the reduction
of disease in treated groups
10. A study is conducted for a pharmaceutical agent that has shown promise
for reducing heart disease among women. In order to more fully test the
agent, an additional study is done restricting the participants to be
randomized to those who have a history of hypertension. Which of the
following advantages cannot be claimed by the researchers?
, NR 503 MIDTERM EXAM REVIEW FINAL EXAM
The generalizability of the study is increased
11. What is the main advantage of the randomization of the 168 study
participants to one of the two drug treatment groups?
Reduces selection bias
12. After entry into the study, patients were first classified into three groups,
those who had a previous AMI, those with a first AMI who were at high risk
for other cardiovascular diseases such as congestive heart failure, and
those with a first AMI who were at low risk for other cardiovascular
diseases. Which term best describes the study design?
Randomized clinical trial with stratified randomization
13. After assignment to treatment group, 77% of those in the placebo group
were men, while 80% of those in the drug X group were men. Which
statement is most likely to be true?
Randomization was successful since the investigators did not alter the
selection of participants in either group in order to ensure equal
percentages of men
14. A preliminary analysis was conducted after 6 months and found that 87%
of participants in the placebo group and 85% of those in the drug X group
had taken more than 90% of their prescribed dosages. Which statement
best describes this finding?
The characteristics of patients who failed to comply with the treatment dosages should be
assessed as they may differ from those who complied
15. Which of the following statements best describes the reason for conducting
the study as a double- blind trial?
Double blinding ensures that potential biases regarding selection, follow-up,
and analysis can be reduced
A multicenter double-blind randomized study was carried out to compare
the effect of drug X with that of a placebo in patients surviving acute
myocardial infarction (AMI). Treatment with the drug started 7 days after
infarction in 1,884 patients, 52% of all persons who were evaluated for
entry into the study. 945 participants were randomized to treatment with
drug X while 939 were assigned to the placebo group. Patients were then
followed for 12 months for reinfarction. There were 152 deaths in the
placebo group and 98 in the group receiving drug X.
